Skip to main content
. 2024 Aug 2;3(8):1138–1147. doi: 10.1016/j.gastha.2024.07.018

Figure 1.

Figure 1

Treatment responses among all patients according to the serum anti-PD-1 autoantibody levels. (A) The bar chart showing the best response to Atezo/Bev therapy determined by the radiological assessment among all patients when the patients were divided into 2 groups (high and low) by the median value of the serum anti-PD-1 autoantibody (anti-PD-1 AAb) levels. (B) The Kaplan-Meier curve for the PFS among all patients divided into 2 groups according to the serum anti-PD-1 AAb levels (high and low). PFS was not affected by the serum anti-PD-1 AAb levels in all patients. The P value was determined by the Wilcoxon test. (C) The Kaplan-Meier curve for OS among all patients divided into 2 groups according to the serum anti-PD-1 AAb levels (high and low). The OS among patients who had lower serum anti-PD-1 AAb levels showed better OS rates, but the difference was not statistically significant. The P value was determined by the Wilcoxon test.